Traditional Chinese medicine composition for treating nerve injury caused by chemotherapy and application thereof

Through the effects of traditional Chinese medicine compositions Chuanxiong, Weilingxian, Chicken Blood Vine, Lianqiancao, Xu Changqing, Mugwort and Boron, the nerve damage caused by chemotherapy drugs is relieved, and the nerves caused by chemotherapy drugs are solved. The problem of poor injury treatment is significantly improved by the patient's pain and quality of life.

CN118924813APending Publication Date: 2024-11-12THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411143332.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The treatment of nerve damage (CIPN) caused by existing chemotherapy drugs is poor, and patients have long-term pain, numbness and walking disorders during chemotherapy and during rehabilitation, which affects the quality of life and treatment effect.

Method used

Provide a traditional Chinese medicine composition, including Chuanxiong, Weilingxian, Chicken Blood Vine, Lianqiancao, Xu Changqing, Mugwort and Botany. Through the effects of dispelling wind and detoxifying, promoting blood circulation and unblocking meridians, it alleviates the symptoms of peripheral neuropathy caused by chemotherapy and improves Nerve cell disordered state.

Benefits of technology

It significantly alleviates the mechanical pain threshold, hypoxic environment and neurotrophic of the ganglion caused by peripheral neuropathy in chemotherapy, reduces the NCI-CTCAE grading and FACT-Ntx scores in patients, improves the quality of life and TCM syndrome scores in patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005001542760000071
    Figure BDA0005001542760000071
  • Figure BDA0005001542760000091
    Figure BDA0005001542760000091
  • Figure BDA0005001542760000092
    Figure BDA0005001542760000092
Patent Text Reader

Abstract

The invention discloses a traditional Chinese medicine composition for treating nerve injury caused by chemotherapy and application thereof. The traditional Chinese medicine composition comprises the following raw materials in percentage by weight: 6-15% of ligusticum wallichii, 15-20% of radix clematidis, 15-20% of caulis spatholobi, 15-20% of glechoma longituba, 15-20% of cynanchum paniculatum, 15-20% of folium artemisiae argyi and 2-6% of borneol. According to the traditional Chinese medicine composition formula, wind dispelling, detoxification, blood circulation promoting and collateral dredging are used as methods, ligusticum wallichii is used as a monarch drug, blood circulation promoting, qi circulation promoting, wind dispelling, pain relieving and collateral dredging can be achieved, and the traditional Chinese medicine composition formula is used for treating rheumatic arthralgia, limb numbness and middle pathogenesis. Radix clematidis and caulis spatholobi are used as ministerial drugs, caulis spatholobi is used for promoting blood circulation, enriching blood and relaxing tendons and activating collaterals, glechoma longituba, cynanchum paniculatum and folium artemisiae argyi are used as assistants, glechoma longituba is used for clearing away heat and toxic materials, diminishing swelling and dissipating blood stasis, cynanchum paniculatum is used for relieving pain and itching, dispelling wind and eliminating dampness, and folium artemisiae argyi is used for warming meridians and dissipating stasis. The borneol is used as a guide, so that the effects of clearing heat and relieving pain can be enhanced, the medicine absorption can be promoted, and the borneol is a medicine for guiding channels. All the medicines are used together to achieve the effects of dispelling wind, dredging collaterals, promoting blood circulation and detoxifying.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine, and specifically relates to a traditional Chinese medicine composition for treating nerve damage caused by chemotherapy and application thereof. Background Art

[0002] Cancer, also known as malignant tumor, is caused by malignant cell proliferation and is invasive and metastatic. According to the China Cancer Registry Annual Report, the number of new cancer cases in the country is about 4.064 million each year. Common treatments for cancer include surgery, chemotherapy, radiotherapy, etc. The clinical treatment of advanced tumors is mainly based on anti-tumor chemotherapy drugs. Chemotherapy drugs can cause nerve damage, namely CIPN (chemotherapy-induced peripheral neuropathy), which refers to the damage caused by chemotherapy drugs to peripheral nerve function, as well as a series of neurological dysfunction symptoms and signs. CIPN is mainly manifested by symptoms such as pain, numbness, and weakness. For example, some patients often feel numbness in their lips, hands and feet after chemotherapy, loss of tactile sensation, accompanied by dull pain, electric shock-like pain. After using oxaliplatin, some patients experience cold-induced sensory impairment and neuropathic pain; after using taxanes, related peripheral neuropathy mainly occurs in the feet and hands, which can be manifested as abnormal position distribution of socks and gloves; after using capecitabine, some patients will experience discoloration or loss of nails. Cumulative toxicity can also cause walking difficulties due to slow fine motor skills and / or impaired body sensation. Surveys and studies have shown that the impact of CIPN on chemotherapy patients is common and lasting. The incidence of chemotherapy-induced peripheral neuropathy in the first month after chemotherapy is as high as 68.1%, and 60% after three months. Until six months after the end of the chemotherapy course, about 30% of patients continue to suffer from peripheral neuropathy. The occurrence of CIPN will not only limit the continued application of chemotherapy regimens and drug selection during the treatment process, but also delay the patient's recovery process, affect the quality of life, and reduce the patient's treatment benefits.

[0003] At present, the main drugs for treating nerve damage caused by chemotherapy drugs include duloxetine, B vitamins, niacin, niacinamide, amitriptyline, serotonin, venlafaxine, gabapentin, pregabalin, etc. In a prospective, double-blind, randomized controlled trial, 26 patients with CIPN pain caused by oxaliplatin, docetaxel and paclitaxel received cross-treatment with pregabalin and placebo for 28 days. The results showed that pregabalin was superior to placebo in relieving the most severe pain in patients with CIPN caused by oxaliplatin (35.4% vs 14.6%, P < 0.05), but compared with the baseline, there was no significant difference between pregabalin and placebo in reducing the average daily pain or the most severe pain. In general, the effectiveness of current CIPN drug treatment needs to be further improved, and more effective CIPN prevention and treatment drugs are yet to be developed.

[0004] Traditional Chinese medicine is one of the important means to treat peripheral neuropathy with symptoms of limb paralysis, pain, and fatigue. Studies have shown that a variety of Chinese herbal compound prescriptions, Chinese patent medicine preparations, and external Chinese medicine treatments can improve the symptoms of peripheral neuropathy. However, there are relatively few studies on traditional Chinese medicine for chemotherapy-related peripheral neurotoxicity. Therefore, it is necessary to further study and develop corresponding drugs. Summary of the invention

[0005] The present invention aims at the above-mentioned problems, makes up for the deficiencies of the prior art, and provides a Chinese medicine composition for treating chemotherapy-induced nerve damage to solve the problems arising from the above-mentioned background technology.

[0006] In a first aspect, the present invention provides a traditional Chinese medicine composition for treating chemotherapy-induced nerve damage, the traditional Chinese medicine composition comprising the following raw materials in weight percentage: 6-15% of Chuanxiong, 15-20% of Clematis, 15-20% of Millettia reticulata, 15-20% of Cynanchum wilfordii, 15-20% of Cynanchum chinense, 15-20% of Artemisia argyi, and 2-6% of Borneol.

[0007] Introduction of Chinese medicine components:

[0008] Chuanxiong: It is the dried rhizome of the plant Chuanxiong of the genus Ligusticum in the Apiaceae family. It has the effects of promoting blood circulation and qi, dispelling wind and relieving pain. It is mainly used for chest pain caused by heart blood stasis, flank pain caused by liver depression and qi stagnation, chest and flank stabbing pain caused by liver blood stasis, injuries caused by falls due to blood stasis, sores and swelling, irregular menstruation, amenorrhea and dysmenorrhea, postpartum blood stasis and pain, lochia retention, various headaches and rheumatic pain, etc.

[0009] Clematis: It is the dried root and rhizome of Clematis, Clematis chinensis or Clematis edulis of the genus Clematis in the Ranunculaceae family. It has the effects of removing rheumatism, dredge meridians and relieve pain, and eliminate bone stagnation. It is mainly used to treat rheumatic arthralgia, bone carp throat, traumatic injuries, headache, toothache, epigastric pain, phlegm and fluid, choking, gynecological masses, breast lumps, etc.

[0010] Millettia reticulata: It is the dried vine stem of the plant Millettia reticulata of the Leguminosae family. It has the effects of promoting blood circulation, replenishing blood, regulating menstruation, and relaxing muscles and tendons. It is mainly used to treat irregular menstruation, dysmenorrhea, amenorrhea, rheumatic pain, numbness of hands and feet, paralysis of limbs, and chlorosis due to blood deficiency.

[0011] Lianqiancao: It is the dried aerial part of the plant Huoxuedan of the Lamiaceae family. It has the effects of promoting dampness and relieving stranguria, clearing away heat and detoxifying, dispersing blood stasis and reducing swelling. It is mainly used to treat stranguria caused by heat, stranguria caused by stones, damp-heat jaundice, swelling and pain caused by sores and carbuncles, and injuries caused by falls.

[0012] Xu Changqing: It is a perennial upright herb of the genus Leucanthemum in the Apocynaceae family. It has the effects of promoting blood circulation and dispelling wind, relieving pain and swelling, regulating immunity, calming, analgesic, improving myocardial ischemia, anti-virus, anti-inflammatory, and anti-allergic. It is mainly used to treat rheumatic arthralgia, low back pain, pain caused by falls, abdominal pain, toothache, etc.

[0013] Artemisia argyi: It is the dried leaves of the Asteraceae plant Artemisia argyi. It has the effects of warming the meridians and stopping bleeding, dispelling cold and relieving pain, and removing dampness and relieving itching when used externally. It is mainly used to treat vomiting blood, epistaxis, metrorrhagia, menorrhagia, fetal bleeding, cold pain in the lower abdomen, irregular menstruation, and infertility due to cold uterus; it is also used externally to treat skin itching.

[0014] Borneol: Synthetic borneol. It is composed of borneol (not less than 55.0%). It has the effects of refreshing the mind, clearing away heat and relieving pain. It is mainly used to treat fever, coma, convulsions, stroke, phlegm, qi stagnation, coma, red eyes, mouth sores, sore throat, and pus in the ear canal.

[0015] According to Chinese medicine, chemotherapy-related peripheral neurotoxicity can be attributed to the category of "blood stasis" and "paralysis" in traditional Chinese medicine. This disease is caused by drug toxicity, wind blocking the collaterals, and blocking the qi and blood. Over time, the limbs become useless and insensitive. The Chinese medicine composition of the present invention is based on the method of dispelling wind and detoxification, promoting blood circulation and unblocking the collaterals. The prescription uses Chuanxiong as the main medicine, promoting blood circulation and qi circulation, dispelling wind and relieving pain, and can "bypass the collaterals" for rheumatic arthralgia and limb numbness, which is the right pathogenesis. The minister uses Clematidis and Millettia Spatholobi, uses Clematidis to dispel wind and relieve arthralgia, Millettia Spatholobi to promote blood circulation and replenish blood, relax muscles and activate collaterals, and is assisted by Herba Lycopodii, Radix Cynanchifoliae, and Folium Artemisiae Argyi. Among them, Herba Lycopodii clears away heat and detoxifies, reduces swelling and disperses blood stasis, Herba Cynanchifoliae relieves pain and itching, dispels wind and dampness, and Folium Artemisiae Argyi warms the meridians and disperses blood stasis. Borneol is used as a messenger, which can not only enhance the effect of clearing heat and relieving pain, but also promote drug absorption, which is a medicine for guiding meridians. The combination of these medicines can dispel wind, dredge meridians, promote blood circulation and detoxify.

[0016] Furthermore, the Chinese medicine composition comprises the following raw materials in weight percentage: 8-12% of Chuanxiong, 16-19% of Clematis, 16-19% of Millettia reticulata, 16-19% of Cynanchum wilfordii, 16-19% of Cynanchum chinense, 16-19% of Artemisia argyi, and 3-5% of Borneol.

[0017] Furthermore, the Chinese medicine composition includes the following raw materials in percentage by weight: 9% of Chuanxiong, 17.5% of Clematis, 17.5% of Millettia reticulata, 17.5% of Herba Cynanchifoliae, 17.5% of Cynanchum wilfordii, 17.5% of Artemisia argyi, and 3.5% of Borneol.

[0018] Furthermore, the preparation method of the Chinese medicine composition comprises the following steps: weighing the raw materials according to weight percentage, crushing, extracting with an extractant, and collecting the extract.

[0019] Furthermore, the extractant is at least one of ethanol and water; the extractant is used for condensation reflux extraction 1-3 times, and each extraction time is 1-3 hours.

[0020] Furthermore, the preparation method also includes filtering, blending, degassing, sterilizing, concentrating and filling the extract.

[0021] Furthermore, the filtration includes coarse filtration and fine filtration, and the filtration times are at least 2 times.

[0022] In a second aspect, the present invention also provides use of the above-mentioned Chinese medicine composition in treating chemotherapy-induced nerve damage.

[0023] In a third aspect, the present invention further provides a drug for treating chemotherapy-induced nerve damage, the drug comprising the above-mentioned Chinese medicine composition and pharmaceutically acceptable excipients.

[0024] Furthermore, the dosage form of the drug includes lotion, tincture, oil, emulsion, ointment, plaster or gel, and further, the dosage form of the traditional Chinese medicine composition is lotion.

[0025] Compared with the prior art, the present invention has the following beneficial effects:

[0026] The Chinese medicine composition of the present invention is based on the method of dispelling wind and detoxifying, promoting blood circulation and unblocking collaterals. The prescription uses Chuanxiong as the main medicine, and uses Clematis chinensis and Millettia reticulata as the assistants, and is supplemented with Herba Lycopodiellae, Cynanchum indica, and Artemisia argyi, and borneol as the messenger. The medicines are used together to play the effects of dispelling wind, unblocking collaterals, promoting blood circulation, and detoxifying. At the same time, the results of previous pharmacological studies have confirmed that chemotherapy drugs may cause stress or inflammatory reactions in cells. The Chinese medicine composition can improve the disordered state of nerve cells, effectively alleviate the mechanical pain threshold of chemotherapy peripheral neuropathy, alleviate the hypoxic environment reflected by HIF1α (hypoxia inducible factor-1), and effectively nourish the nerves of the dorsal root ganglion, thereby effectively reducing the NCI-CTCAE (National Cancer Institute of the United States toxicity grading standard) grade of the patient, FACT-Ntx score (a tool for assessing the quality of life of patients with chronic pain), PS (physical condition) score, and significantly improve the TCM syndrome score of the patient, indicating that the Chinese medicine composition of the present invention can significantly improve the symptoms of limb paralysis, pain, fatigue, etc. of peripheral neuropathy caused by chemotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is a schematic diagram of the changes in mechanical pain threshold test of SD rats in each group;

[0028] Figure 2 This is a schematic diagram of the HE staining results of rat dorsal root ganglion;

[0029] Figure 3 Schematic diagram of the activation of dorsal root ganglion microglia between the blank group and the model group detected by IHC technology;

[0030] Figure 4 This is a schematic diagram of the expression of HIF1α in dorsal root nerves of different groups detected by IHC technology;

[0031] Figure 5 This is a schematic diagram of Western Blot detection of hypoxia stress response and neurotrophic proteins;

[0032] Figure 6It is a schematic diagram of LC-MS / MS (liquid chromatography-mass spectrometry) detection and analysis of differential metabolites of a traditional Chinese medicine composition;

[0033] Figure 7 Schematic diagram of variance analysis for CIPN grading data;

[0034] Figure 8 This is a schematic diagram of the rank sum test analysis of CIPN grading data;

[0035] Fig. 9 Schematic diagram of the ANOVA for FACT-Ntx subscale score data;

[0036] Fig.10 Schematic diagram of rank sum test analysis of FACT-Ntx subscale score data;

[0037] Fig.11 Schematic diagram of variance analysis for PS scoring data;

[0038] Fig.12 This is a schematic diagram of the rank sum test analysis of PS score data;

[0039] Fig.13 This is a schematic diagram of variance analysis of TCM syndrome scale scoring data;

[0040] Fig.14 This is a schematic diagram of the rank sum test analysis of the TCM syndrome scale scoring data. DETAILED DESCRIPTION

[0041] The following will be combined with the accompanying drawings in the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the protection scope of the present invention.

[0042] The Chinese medicine combination and the preparation method thereof of the present invention are further described below through specific examples.

[0043] Example 1

[0044] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 9% of chuanxiong, 17.5% of clematis, 17.5% of millettia reticulata, 17.5% of spatholobi, 17.5% of cyperus rotundus, 17.5% of cyperus rotundus, 17.5% of mugwort leaf, and 3.5% of borneol.

[0045] The preparation method of the Chinese medicine lotion for treating chemotherapy-induced nerve damage in this embodiment is as follows:

[0046] S1: mixing the raw materials according to weight percentage, washing and crushing them;

[0047] S2 condenses and refluxes the crushed raw material in S1 with water 8 and 6 times the weight of the raw material, respectively, for 2 times, and each extraction time is 1 hour;

[0048] S3 After the combined extracts are filtered coarsely once, they are clarified with a clarifier and then filtered once with a fine filter;

[0049] The filtered juice from S4 is blended according to the relevant national beverage standards;

[0050] S5 degasses the prepared juice with a vacuum degasser, homogenizes it with a high-pressure homogenizer, sterilizes it with a pasteurization method, and then cools it; concentrates the obtained liquid with a vacuum method, and fills and seals it under sterile conditions to obtain a lotion.

[0051] Example 2

[0052] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 6% of chuanxiong, 15% of clematis, 15% of millettia reticulata, 20% of schizonepeta tenuifolia, 20% of cynanchum wilfordii, 20% of argyi, and 4% of borneol.

[0053] The preparation method of the Chinese medicine lotion in this embodiment is consistent with that in Example 1.

[0054] Example 3

[0055] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 15% of chuanxiong, 20% of clematis, 15% of millettia reticulata, 15% of spatholobi, 15% of cyperus rotundus, 15% of cyperus rotundus, 15% of mugwort leaf, and 5% of borneol.

[0056] The preparation method of the Chinese medicine lotion in this embodiment is consistent with that in Example 1.

[0057] Example 4

[0058] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 15% of chuanxiong, 15% of clematis, 20% of millettia reticulata, 15% of spatholobi, 15% of cynanchum wilfordii, 15% of cynanchum chinense, 15% of mugwort leaf, and 5% of borneol.

[0059] The preparation method of the Chinese medicine lotion in this embodiment is consistent with that in Example 1.

[0060] Example 5

[0061] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 9% of chuanxiong, 18% of clematis root, 18% of millettia reticulata, 18% of spatholobi, 18% of cyperus rotundus, 18% of cyperus rotundus, 18% of argyi leaf, 17% of borneol.

[0062] The preparation method of the Chinese medicine lotion in this embodiment is consistent with that in Example 1.

[0063] Example 6

[0064] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 9% of chuanxiong, 17% of clematis, 17% of millettia reticulata, 17% of spatholobi, 17% of cyperus rotundus, 17% of cyperus rotundus, 17% of argyi, and 6% of borneol.

[0065] The preparation method of the Chinese medicine lotion in this embodiment is consistent with that in Example 1.

[0066] Example 7

[0067] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 8% of chuanxiong, 19% of clematis root, 19% of millettia reticulata, 16% of smilax glabra, 16% of cyperus rotundus, 17% of argyi leaf and 5% of borneol.

[0068] The preparation method of the Chinese medicine lotion in this embodiment is consistent with that in Example 1.

[0069] Example 8

[0070] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 12% of chuanxiong, 16% of clematis, 16% of millettia reticulata, 19% of smilax glabra, 18% of cyperus rotundus, 16% of argyi and 3% of borneol.

[0071] The preparation method of the Chinese medicine lotion in this embodiment is consistent with that in Example 1.

[0072] Example 9

[0073] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 12% of chuanxiong, 16% of clematis, 16% of millettia reticulata, 16% of spatholobi, 18% of cynanchum wilfordii, 19% of argyi and 3% of borneol.

[0074] The preparation method of the Chinese medicine lotion in this embodiment is consistent with that in Example 1.

[0075] Example 10

[0076] A traditional Chinese medicine composition for treating nerve damage caused by chemotherapy, comprising the following raw materials in percentage by weight: 12% of chuanxiong, 16% of clematis, 16% of millettia reticulata, 17% of schizonepeta tenuifolia, 19% of cynanchum wilfordii, 17% of mugwort leaf and 3% of borneol.

[0077] The preparation method of the Chinese medicine lotion in this embodiment is consistent with that in Example 1.

[0078] In order to better understand the present invention, the basic pharmacological experiments and clinical trial results of specific embodiments of the present invention are used below to illustrate its effects.

[0079] 1. Basic pharmacological experiments

[0080] The specific embodiment of the present invention selects natural plant medicine as raw material, complies with the national compound medicine law and regulations, and utilizes the comprehensive effects of various Chinese medicines to treat chemotherapy-induced nerve damage.

[0081] 1. Experimental groups:

[0082] Fifty healthy female SD rats, weighing 180±20 g, were fed adaptively for 1 week and then divided into 5 groups (blank control group / NORMAL, model group / MODEL, low-dose group / TLHXF LOW group, medium-dose group / TLHXF MIDDLE group, high-dose group / TLHXF HIGH group) according to their weight using a random number table method, with 10 rats in each group.

[0083] Modeling: Rats in MODEL, TLHXF LOW, TLHXF MIDDLE, and TLHXF HIGH groups were intraperitoneally injected with paclitaxel (8 mg / kg) once every 3 days for 3 consecutive times (on the 1st, 4th, and 7th days, respectively), with a cumulative dose of 24 mg / kg. Rats in NORMAL group were intraperitoneally injected with an equal volume of normal saline.

[0084] 2. Dosage method:

[0085] After successful modeling, the limbs and tails of rats in the TLHXF LOW, TLHXF MIDDLE, and TLHXF HIGH groups were immersed in the corresponding dose of the Chinese medicine lotion shown in Example 1 from 1 day before modeling to the 12th day of modeling, with the temperature controlled at about 35°C, twice a day, each time for 20 minutes; the rats in the NORMAL and MODEL groups were immersed in warm water, twice a day, each time for 20 minutes. Special containers were used for drug administration to ensure that the limbs and tails of the rats were completely immersed, and the limbs and tails of the rats were wiped dry after each immersion.

[0086] Drug configuration: The body surface area of ​​an adult is about 1.6 to 1.9 square meters. According to the body surface area (BSA) calculation formula, the body surface area conversion factor for humans is 37, while the body surface area conversion factor for rats is 6.2. Based on the calculation of the Rule of Nines, the body surface area of ​​the hands and feet of the human body accounts for about 4.6% of the total body surface area. Assuming that the average weight of the sample is 0.25 kg, the medium dose is set as the benchmark dose, that is, 71.5 g / kg, the low dose is half of the medium dose, that is, 35.75 g / kg, and the high dose is twice the medium dose, that is, 143 g / kg.

[0087] 3. Behavioral testing:

[0088] Von Frey test: On the 1st, 3rd, 6th, 9th and 12th day of modeling, rats were placed on a metal net and covered with a transparent plexiglass cover. The rats were allowed to adapt to the environment for 15 minutes before the test. After the combing and exploration activities basically disappeared, each rat was stimulated with Von Frey fibers vertically and forcefully on the sole of the foot. The test was carried out from small to large, with an interval of more than 6 seconds between two stimulations. The value was recorded when the rat showed a behavioral response of lifting the foot or licking the paw, and then repeated 5 times. The mean (± standard deviation) of each rat was used to represent its pain threshold value. Behavioral testing was performed before other operations.

[0089] like Figure 1 As shown in Table 1, there was no significant difference in the baseline behavioral test of each group. After paclitaxel injection to rats, the mechanical pain threshold of the MODEL group (9.35±2.20), TLHXF LOW group (10.75±2.32), TLHXF MIDDLE group (10.50±3.16) and TLHXF HIGH group (10.50±3.16) decreased compared with the NORMAL group (15.13±1.73) on the 3rd day (P<0.05), but the decrease of each TLHXF group was slower than that of the MODEL group. From the 9th day onwards, the mechanical pain threshold of each TLHXF group showed statistical difference compared with the MODEL group, among which the TLHXF HIGH group was the most obvious (6.00±1.51, 12.00±0.70, p<0.001), indicating that the Chinese medicine composition lotion of the present invention can effectively alleviate the mechanical pain threshold of rats with paclitaxel-induced chemotherapy peripheral neuropathy.

[0090] Table 1 Mechanical pain threshold of rats in each group at different time

[0091]

[0092] Note: * is compared with the normal group, P<0.05, # is compared with the model group, P<0.05

[0093] 4. Pathological testing

[0094] (1) Specimen preparation: On the 12th day of modeling, samples were collected after behavioral testing and immersion in the Chinese medicinal composition lotion of the present invention. Anesthesia was performed using 0.45% sodium pentobarbital, 1 ml / 100 g. Blood was then collected from the abdominal aorta and placed in an anticoagulant tube; the dorsal root ganglia of the L4-L6 segment of the rat and the lumbar enlargement of the spinal cord (i.e., the L4-L6 segment of the spinal cord) were then taken out. The collected blood samples were centrifuged at 2500 rpm for 15 min, and the plasma was collected and stored in a -20°C refrigerator for later use, and then placed in neutral formalin for fixation for 48 hours for specimens for pathological testing.

[0095] (2) HE (hematoxylin-eosin) staining observation: The dorsal root ganglion tissue samples of SD rats in the NORMAL group and the MODEL group were fixed in 4% paraformaldehyde solution for at least 24 hours to ensure that the samples were completely fixed. The corresponding sections were made after dehydration, transparency and embedding. After dewaxing and staining, the sections were sealed to observe the differences in the nuclear and cytoplasmic structures of the dorsal root ganglion tissue samples of the L4-L6 segments of the rats.

[0096] like Figure 2 As shown in the figure, in the blank group, the cell morphology is relatively healthy, the nucleus is clear and the edges are regular. In the pictures of the model group, the arrangement of nerve cells may appear more compact or slightly disordered, with condensation of the nucleus or swelling of the cell body, which may be due to cell stress or inflammatory response caused by chemotherapy drugs, and the TLHXF group improved the disordered state of nerve cells to varying degrees.

[0097] (3) Immunohistochemical index detection: Image-Pro Plus (IPP) software was used to measure the IOD value (integrated optical density) of the stained part in the captured images for quantitative analysis to evaluate the changes of microglia and oxidative stress in the dorsal root ganglia of rats in each group.

[0098] ①Microglial marker (IBA1)

[0099] like Figure 3 As shown, the activation of dorsal root ganglion microglia between the blank group and the model group was detected by IHC technology. It was found that the number of activated microglia in the model group was increased compared with the blank group, with a statistically significant difference (P<0.01).

[0100] ②Hypoxia index (HIF1A)

[0101] like Figure 4 As shown, the expression of HIF1α in dorsal root nerves of different groups was detected by IHC technology, and it was found that the expression of HIF1α in the model group was significantly increased compared with the normal group (P<0.001), and the Chinese medicine composition of the present invention can effectively alleviate the hypoxic environment reflected by HIF1α.

[0102] (4) Western Blot (protein blotting) detection: Western Blot protein development was completed based on gel running, membrane transfer, antibody incubation and ECL color imaging to detect the protein expression levels of ROS, HIF1A, CHOP, BDNF, and TrkB in different groups, and protein quantitative analysis was performed using Image J software.

[0103] like Figure 5As shown, Western blot detected the expression of related proteins: In terms of the WB results of the in vivo paclitaxel-induced chemotherapy peripheral neuropathy model, each group of the Chinese medicine composition of the present invention can effectively reduce the level of HIF1α compared with the model group, indicating an improvement in oxidative supply. In addition, in terms of neuroprotection, the WB results show that each group of the Chinese medicine composition of the present invention can effectively nourish the nerves of the dorsal root ganglion compared with the model group.

[0104] (5) LC-MS / MS (liquid chromatography-mass spectrometry) detection and analysis of differential metabolites of the Chinese medicine composition: Samples were collected 10 days after film formation and administration. Three serum samples were taken from each group of rats. The extract was added under low temperature to extract the metabolites. The supernatant metabolite solvent was then centrifuged and analyzed by liquid chromatography-mass spectrometry.

[0105] like Figure 6 As shown, S1P was screened to be the metabolite with the most obvious difference between the normal group / model group / drug treatment group.

[0106] 2. Clinical Trials

[0107] 1. General Information

[0108] From November 2023 to May 2024, 33 patients from the Cancer Center of the First Affiliated Hospital of Guangzhou University of Chinese Medicine who were receiving taxane and oxaliplatin chemotherapy and had developed chemotherapy-related peripheral neurotoxicity were enrolled, as shown in Table 2 ; the NCI-CTCAE (National Cancer Institute Toxicity Grading Standard) grading (grade 0 to 5) table of the patients evaluated before treatment was shown in Table 3 , and patients who met the diagnosis of chemotherapy-related peripheral neurotoxicity were included in this study.

[0109] Table 2 General information of patients

[0110]

[0111] Table 3 NCI-CTCAE (National Cancer Institute Toxicity Grading Criteria) classification of patients

[0112]

[0113] 2. Inclusion criteria

[0114] Subjects must meet all of the following criteria to be eligible for inclusion in this trial: patients currently receiving taxane or oxaliplatin chemotherapy and who have developed CIPN; aged 18 to 75 years; without cognitive impairment and able to cooperate with the scale filling and follow-up.

[0115] 3. Exclusion criteria

[0116] Patients with a history of neurological illness caused by stress (such as carpal / tarsal tunnel syndrome, radiculopathy, spinal stenosis, brachial plexopathy); patients who are allergic to the ingredients of this product (including those with a history of allergy to the components of the other product); patients with diabetes and peripheral vascular disease; patients with brain or meningeal metastases; patients with significant liver and kidney function abnormalities; patients participating in other clinical trials at the same time; pregnant or lactating women.

[0117] 4. Shedding standards and treatment

[0118] If certain comorbidities, complications, special physiological changes or serious adverse events occur during the trial, the subject should not continue to participate in the trial; the subject refuses to continue to participate in the trial and explicitly requests the researcher to withdraw from the trial; the subject does not explicitly request to withdraw from the trial, but is lost to follow-up for various reasons.

[0119] For cases of withdrawal or loss to follow-up: contact the subjects as much as possible, ask the reasons, and obtain the information required for evaluation as much as possible; for cases of withdrawal due to adverse events or adverse reactions: take appropriate treatment measures based on the actual situation and save the data for analysis.

[0120] 5. Implementation methods

[0121] This study was an open-label, single-arm study and no grouping was performed.

[0122] Intervention options

[0123] Use the Chinese medicine lotion of Example 1 of the present invention, take the liquid medicine, fumigate and wash, and then wet compress the hands and feet. Continue to use the medicine, twice in the morning and evening, each time for 30 minutes, and the method of use is as follows:

[0124] When using, heat the lotion again to 60℃. Do not soak your hands and feet in it immediately. Follow the principle of fumigation first, soaking second, and wet compress three times:

[0125] First fumigation: The temperature is about 60-50℃. If you cannot immerse your hands and feet directly, you can first try to touch the liquid surface with your hands and feet, and let the medicinal gas fumigate the palms of your hands and feet. The fumigation time is not fixed, and it is based on the test to cool the temperature of the medicinal liquid to the upper limit of the patient's tolerance.

[0126] Soak again: The temperature is about 45-40℃, a little hot but tolerable. Soak your feet in the liquid for 20-30 minutes, and carefully feel the changes in body temperature and coordinate with toe movements.

[0127] Wet compress: The temperature is about 33-40℃. When the temperature of the liquid medicine drops to warm and the heat does not have a relatively sensitive stimulation to the skin, cover the hands and feet with cotton yarn or wear thin cloth gloves and thin socks (they can be slightly smaller, so that they feel slightly tight after wearing. Cotton yarn, socks and gloves can be washed and reused repeatedly), and soak them in the liquid medicine. After fully soaking, either leave the liquid medicine or continue to immerse in the liquid medicine for a full wet compress. This process lasts for 10-15 minutes.

[0128] After the wet compress, wash the skin with a small amount of warm water, wipe dry, and the treatment is complete.

[0129] 6. Outcome indicators

[0130] Data were collected 3 weeks ± 3 days after medication, with the change in NCI-CTCAE (National Cancer Institute Toxicity Grading Standard) grade as the primary outcome indicator, and FACT-Ntx score, PS score, and Traditional Chinese Medicine Syndrome Rating Scale as secondary outcome indicators.

[0131] NCI-CTCAE grading changes: A set of standards developed by the National Cancer Institute (NCI) of the United States to evaluate adverse drug events in clinical trials, which is of great significance to the safety of clinical trials and the adjustment of treatment plans.

[0132] Table 4 NCI-CTCAE grading change criteria

[0133]

[0134]

[0135] The FACT-Ntx score is a tool used to assess the quality of life of patients with chronic pain. It can help doctors and researchers understand how patients cope with pain in their lives and the impact of pain on daily activities and emotional state.

[0136] Table 5 FACT-Ntx scores

[0137]

[0138] PS score: a tool used to assess the daily living ability and physical condition of cancer patients. PS score can help doctors understand the patient's activity level, functional status and tolerance to treatment, thus providing a basis for treatment decisions.

[0139] Table 6 PS score

[0140]

[0141]

[0142] TCM Syndrome Rating Scale: A quantitative assessment tool used to evaluate a patient's TCM syndrome. It helps doctors and researchers understand the TCM syndrome manifestations of patients more systematically, judge the severity of the disease and the trend of change, so as to formulate targeted treatment plans and evaluate the efficacy. This scale is suitable for TCM clinical practice and research. By systematically recording and evaluating the patient's symptoms, doctors can understand the patient's physical condition more accurately and provide a basis for formulating personalized TCM treatment plans.

[0143] Table 7 TCM syndrome scoring scale

[0144]

[0145] 7. Data collation and statistical analysis

[0146] All data were processed and analyzed using SPSS 22.0 statistical software. The rank sum test was used to compare the means of all measurement data between the two groups, and the variance analysis was used to compare the means of the self-control before and after the intervention. P<0.05 was considered statistically significant, and P<0.01 was considered statistically significant.

[0147] 8. Experimental results

[0148] After two courses of treatment with the Chinese medicine composition of the present invention, the patient's NCI-CTCAE grade, FACT-Ntx score, PS score and TCM syndrome scoring scale results were significantly improved, indicating that the Chinese medicine composition of the present invention can significantly improve the symptoms of limb paralysis, pain, fatigue and the like caused by peripheral neuropathy caused by chemotherapy.

[0149] (1) Changes in NCI-CTCAE grading

[0150] As shown in Table 3, the total number of CIPN downgrades was 18, of which 5 were downgraded by 2 levels and 13 were downgraded by 1 level, with a positive rate of 54.5%. Figure 7 It can be seen that the variance analysis of the CIPN grading data of the baseline period, the first visit, and the second visit of the enrolled patients showed that P value = 0.011, P < 0.05, indicating that based on the self-control before and after, the CIPN grading change of the patients after treatment with the Chinese medicine composition of the present invention was statistically significant. Figure 8 It can be seen that the CIPN rating data of the baseline period, the first visit, and the second visit of the enrolled patients were subjected to a rank sum test, and the CIPN ratings of the baseline period were compared with those of the first visit and the second visit, P < 0.05, indicating that based on the self-before and after comparison, the CIPN grading changes between the baseline period and the first visit and the second visit of the patients after treatment with the Chinese medicine composition of the present invention were statistically significant, and the CIPN grading was controlled to a certain extent, showing a trend of continuous alleviation.

[0151] (2) FACT-Ntx score

[0152] As can be seen from Table 8, the total number of people whose FACT-Ntx subscale scores decreased was 27, of which 17 decreased by more than 5 points, the symptom relief positive rate was 81.8%, and the clinical effective rate was 51.5%. Fig. 9 It can be seen that the variance analysis of the FACT-Ntx subscale score data of the baseline period, the first visit, and the second visit of the enrolled patients showed that P value = 0.0042, P < 0.05, indicating that based on the self-control before and after, the change in the FACT-Ntx subscale score of the patients after treatment with the Chinese medicine composition of the present invention was statistically significant. Fig.10 It can be seen that the rank sum test was performed on the FACT-Ntx subscale score data of the baseline period, the first visit, and the second visit of the enrolled patients, and the FACT-Ntx subscale scores of the baseline period were compared with those of the first visit and the second visit, P < 0.05, indicating that based on the self-before and after comparison, the changes in the FACT-Ntx subscale scores of the baseline period and the first visit and the second visit of the patients after treatment with the Chinese medicine composition of the present invention have significant statistical significance.

[0153] Table 8 FACT-Ntx scores of patients after 2 courses of treatment

[0154]

[0155]

[0156] (3) PS score

[0157] As can be seen from Table 9, the total number of people with decreased PS scores was 17, with a positive rate of 51.5%. Fig.11 It can be seen that the PS score data of the baseline period, the first visit, and the second visit of the enrolled patients were analyzed by variance analysis, and the P value was 0.0028, P < 0.05, indicating that based on the self-before and after comparison, the PS score change of the patients after treatment with the Chinese medicine composition of the present invention was statistically significant. Fig.12 It can be seen that the PS score data of the baseline period, the first visit, and the second visit of the enrolled patients were subjected to a rank sum test, and the PS scores of the baseline period were compared with those of the first visit and the second visit, P < 0.05, indicating that based on the before and after comparison, the changes in the PS scores of the patients between the baseline period and the first visit and the second visit after treatment with the Chinese medicine composition of the present invention were statistically significant.

[0158] Table 9 PS scores of patients after 2 courses of treatment

[0159]

[0160] (4) TCM Syndrome Rating Scale

[0161] As can be seen from Table 10, the total number of people whose TCM syndrome scale scores decreased was 26, of which 20 patients had a decrease of more than 30%. The TCM syndrome remission positive rate was 78.8%, and the clinical effective rate was 60.6%. Fig.13 It can be seen that the TCM syndrome scale score data of the baseline period, the first visit, and the second visit of the enrolled patients were subjected to variance analysis, and the P value was 0.0028, P < 0.05, indicating that based on the self-control before and after, the TCM syndrome scale score of the patients after treatment with the Chinese medicine composition of the present invention was statistically significant. Fig.14 It can be seen that the rank sum test was performed on the TCM Syndrome Scale score data of the baseline period, the first visit, and the second visit of the enrolled patients, and the TCM Syndrome Scale scores of the baseline period were compared with those of the first visit and the second visit, P < 0.05, indicating that based on the before and after comparison, the changes in the TCM Syndrome Scale scores of the patients between the baseline period and the first visit and the second visit after treatment with the Chinese medicine composition of the present invention have significant statistical significance.

[0162] Table 10 TCM syndrome scoring scale for patients after 2 courses of treatment

[0163]

[0164]

[0165] Treatment Example 1

[0166] Patient Wang, male, 72 years old, was diagnosed with moderately differentiated squamous cell carcinoma of the left lung (with mediastinal and bilateral hilar lymph node metastasis) on August 31, 2023. After 2 courses of chemotherapy containing taxanes, the patient developed severe and intolerable peripheral neuropathy, so that the chemotherapy course was interrupted. Symptoms include numbness and weakness below the elbows and knees of the hands and feet, loss of superficial sensation, inability to hold, inability to walk independently, symptoms that cannot be relieved on their own, and progressively worsen, lower limb muscle strength continues to decrease, and he switches to a wheelchair for travel. On November 9, 2023, the Chinese medicine composition lotion of Example 1 of the present invention was used. Before medication, the severity of the patient's CIPN was assessed on the NCI-CTCAE scale and was assessed as NCI-CTCAE level 4. The patient was followed up after 2 weeks of use. The patient felt that the superficial sensation of the lower limbs was significantly improved, the muscle strength was significantly improved, and he could walk independently with good balance. After one month of use, the patient's peripheral nerve movement and sensory function were further restored, and the patient no longer needed a wheelchair for daily activities. The NCI-CTCAE scale was re-evaluated and graded as level 2. In terms of safety, during the follow-up period, the blood routine, liver function and other test results of the patient before and after the treatment and the skin condition were compared, and no adverse reactions were reported.

[0167] Treatment Example 2

[0168] Patient Chen, male, 60 years old, was diagnosed with left lung adenocarcinoma (with multiple metastases to the left adrenal gland, bilateral supraclavicular fossa, hilar, and mediastinal lymph nodes, T2bN3Mla IVA stage) by imaging and pathological biopsy in September 2023. From September 2023 to November 2023, the patient underwent 3 courses of targeted therapy: Nimotuzumab. Review and evaluation on December 1, 2023, the efficacy was PD. On December 5, 2023, the patient underwent the first course of chemotherapy + targeted + immunotherapy, with the regimen: white purple + loplatin + bevacizumab + carrelizumab. After treatment, the patient developed obvious symptoms of peripheral neuropathy, with obvious numbness and tingling in the lower limbs, affecting the walking balance function and limiting daily activities. On December 10, 2023, the Chinese medicine composition lotion of Example 1 of the present invention was started. After 2 weeks of use, the patient was followed up. The patient felt that the shallow sensation of the lower limbs was significantly improved, the tingling sensation had disappeared, and there was no hindrance to daily walking. In terms of safety, after close follow-up, patients had a good medication experience during use and no adverse reactions were reported.

[0169] The present invention is further described above with the aid of specific embodiments. However, it should be understood that the specific description here should not be construed as limiting the essence and scope of the present invention. Various modifications made to the above embodiments by ordinary technicians in the field after reading this specification are all within the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for treating chemotherapy-induced nerve damage, characterized in that: The Chinese medicine composition comprises the following raw materials in percentage by weight: 6-15% of chuanxiong, 15-20% of clematis, 15-20% of millettia reticulata, 15-20% of cyperus rotundus, 15-20% of cyperus rotundus, 15-20% of cyperus rotundus, 15-20% of argyi, and 2-6% of borneol.

2. A Chinese medicine composition for treating chemotherapy-induced nerve damage according to claim 1, characterized in that: The Chinese medicine composition comprises the following raw materials in percentage by weight: 8-12% of chuanxiong, 16-19% of clematis, 16-19% of millettia reticulata, 16-19% of spatholobi, 16-19% of cyperus rotundus, 16-19% of cyperus rotundus, 16-19% of argyi, and 3-5% of borneol.

3. A Chinese medicine composition for treating chemotherapy-induced nerve damage according to claim 1, characterized in that: The Chinese medicine composition comprises the following raw materials in percentage by weight: 9% of chuanxiong, 17.5% of clematis root, 17.5% of millettia reticulata, 17.5% of spatholobi, 17.5% of cyperus rotundus, 17.5% of cyperus rotundus, 17.5% of argyi leaf, and 3.5% of borneol.

4. A Chinese medicine composition for treating chemotherapy-induced nerve damage according to any one of claims 1 to 3, characterized in that: The preparation method of the traditional Chinese medicine composition comprises the following steps: weighing raw materials according to weight percentage, crushing, extracting with an extractant, and collecting the extract.

5. A Chinese medicine composition for treating chemotherapy-induced nerve damage according to claim 4, characterized in that: The extractant is at least one of ethanol and water; the extractant is used for condensation reflux extraction 1-3 times, and each extraction time is 1-3 hours.

6. A Chinese medicine composition for treating chemotherapy-induced nerve damage according to claim 4, characterized in that: The preparation method also includes filtering, blending, degassing, sterilizing, concentrating and filling the extract.

7. A Chinese medicine composition for treating chemotherapy-induced nerve damage according to claim 6, characterized in that: The filtration includes coarse filtration and fine filtration, and the filtration times are at least 2 times.

8. Use of the Chinese medicine composition according to any one of claims 1 to 7 in treating chemotherapy-induced nerve damage.

9. A drug for treating chemotherapy-induced nerve damage, characterized in that: The medicine comprises the Chinese medicine composition according to any one of claims 1 to 7, and pharmaceutically acceptable excipients.

10. The drug for treating chemotherapy-induced nerve damage according to claim 9, characterized in that: The dosage form of the drug includes lotion, tincture, oil, emulsion, ointment, plaster or gel.

Citation Information

Patent Citations

  • Medicinal material for treating stroke and preparation method thereof

    CN110464805A